# Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

> **NCT00808132** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 1886 (actual)

## Conditions studied

- Menopause
- Osteoporosis

## Interventions

- **DRUG:** bazedoxifene 20 mg/ conjugated estrogens 0.45 mg
- **DRUG:** bazedoxifene 20 mg/ conjugated estrogens 0.625 mg
- **DRUG:** bazedoxifene 20 mg
- **DRUG:** conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00808132
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 1886 (ACTUAL)
- **Last updated:** 2014-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00808132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00808132, "Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00808132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*